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Summary We describe here the results of an analysis of Plasmodium falciparum multidrug
resistance protein 1 (pfmdr1) gene copy number from 440 ﬁeld isolates from Papua New Guinea.
No multiple copies of the gene were found, which corresponds to the lack of usage of meﬂo-
quine. These data extend regional knowledge about the distribution of multidrug-resistant
P. falciparum.Drug resistance;
Gene ampliﬁcation; © 2008 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All rights
p
t
rpfmdr1;
Papua New Guinea
reserved.
1. Introduction
Recent in vitro and in vivo studies showed an associa-
tion between artesunate—meﬂoquine therapy failure and
genetic changes in Plasmodium falciparum multidrug resis-
tance protein 1 (pfmdr1) gene (Price et al., 2004; Sidhu
et al., 2006). These ﬁndings underline the contribution of
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o antimalarial drugs. Most malaria-endemic countries have
ecently adopted artemisinin combination therapies (ACTs)
s ﬁrst-line therapy for P. falciparum infections because
f increasing resistance to all currently used antimalarial
rugs.
As the world’s most multidrug-resistant P. falciparum
arasites are found along the borders of Thailand and are
lso emerging elsewhere in Southeast Asia, many studies on
fmdr1 gene copy number have been performed on samples
rom Southeast Asia. Studies in Africa indicate that pfmdr1
ene copy number is rare in the ﬁeld outside Southeast
sia (Ursing et al., 2006). However, no research has been
onducted on pfmdr1 copy number in Papua New Guinea
PNG), where drug pressure of meﬂoquine on P. falciparum
as been minimal so far. Until recently, standard ﬁrst-line
e and Hygiene. Published by Elsevier Ltd. All rights reserved.
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reatment in PNG for malaria consisted of chloroquine or
modiaquine plus sulfadoxine—pyrimethamine. In order to
escribe the baseline situation, we determined pfmdr1 copy
umbers in 440 ﬁeld isolates from PNG. With this analysis
e extend the knowledge about the global distribution of
ultidrug-resistant P. falciparum.
. Materials and methods
re-treatment ﬁngerprick samples were collected from 440
atients within several in vivo drug efﬁcacy studies con-
ucted between 2003 and 2005 in three health centres in
imbu, East Sepik and Madang Province in PNG (Marfurt et
l., 2007).
The pfmdr1 gene copy number was assessed as described
reviously (Price et al., 2004). The assays were run in trip-
icate on an Applied Biosystems 7500 real-time PCR system
Applied Biosystems, Rotkreuz, Switzerland) and every run
ontained two calibrator DNA samples from clones 3D7 and
2-mef, having pfmdr1 copy numbers of 1 and 3, respec-
ively. The Ct threshold was set manually at 0.05 for pfmdr1
nd at 0.03 for -tubulin, respectively, and the baseline was
alculated automatically. Results were analysed by the com-
arative Ct method described previously (Price et al.,
004). Assays were repeated if one of the following results
as obtained: no Ct value for more than one sample in the
riplicate; calibrator copy number /= 3; Ct spread >1.5;
t values >35.
Themultiplicity of infection was determined as described
reviously by fragment-sizing of P. falciparum merozoite
urface protein 2 (pfmsp2) using GeneMapper Software,
3.7 (Applied Biosystems) (Falk et al., 2006). The primary
nd nested PCR protocol was changed to 2min at 94 ◦C
ollowed by 25 cycles (30 s at 94 ◦C, 45 s at 50 ◦C and
min 30 s at 70 ◦C) with a ﬁnal elongation for 10min at
0 ◦C each. Of the diluted nested PCR product (1:10 in
2O), 2.5l were combined with 10l diluted ROX-500 size
tandard (1:40 in H2O; Applied Biosystems). Assays were
epeated if one of the following results was obtained: no
izing data; pfmsp2 PCR artefacts; no pfmsp2 PCR prod-
ct.
Samples were excluded from the ﬁnal analysis if one
r more of the following results were obtained after rep-
tition of the assay: no Ct value for more than one
ample in triplicate; Ct spread >1.5; Ct values >35;
fmsp2 PCR artefacts; no sizing data; no pfmsp2 PCR prod-
ct.
. Results
f the 440 samples analysed, 35 were excluded from the
nal analysis (15 no Ct value for more than one sample in
riplicate; one Ct value >35; three no Ct value for more than
ne sample in triplicate and no pfmsp2 PCR product; six no
izing data; three pfmsp2 PCR artefacts; seven no pfmsp2
CR product). The remaining 405 samples included in the
nal analysis showed only one copy of the pfmdr1 gene.
he mean multiplicity of infection found in the patients was
.56± 0.76 (mean± SD), with 240 patients showing single
nfections.
FE.M. Hodel et al.
. Discussion
he number of samples excluded from the ﬁnal analysis
ight be explained by the fact that ﬁeld samples sometimes
ontain very low levels of parasite DNA, thus leading to inde-
erminable Ct values in the real-time PCR or missing pfmsp2
CR products.
Meﬂoquine use has not been signiﬁcant yet in PNG,
nd the occurrence of only one gene copy of pfmdr1
trengthens the assumption that meﬂoquine selects for copy
umber increase. Studies that have tested different P. falci-
arum isolates from PNG for meﬂoquine resistance showed
ull in vitro susceptibility (Hombhanje, 1998). By contrast,
ther authors previously have shown a high frequency of
fmdr1 sequence polymorphisms, conﬁrming that chloro-
uine selects for polymorphisms (Nagesha et al., 2001).
The multiplicity of infections found is similar to results
n other settings in PNG (Cortes et al., 2004). However, it is
ossible that a small percentage of the parasites in multi-
le infections carry more than one copy of pfmdr1 and will
ot appear as multiple copies in the analysis due to lack of
tatistical power. In addition, the fact that within the large
umber of single infections there was no gene ampliﬁcation
upports the idea that pfmdr1 is still not ampliﬁed in PNG.
In conclusion, we show that drug-resistance-associated
fmdr1 gene ampliﬁcations have not yet been selected in
NG. Therefore meﬂoquine and artesunate might still be
ighly effective ﬁrst-line treatment options against P. falci-
arum infections.
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